Method for removal of viruses from blood by lectin affinity hemodialysis

• US 10,022,483 B2
• Filed: 09/18/2014
• Issued: 07/17/2018
• Est. Priority Date: 01/17/2003
• Status: Active Grant

• Current Assignee: Aethlon Medical, Inc.
• Original Assignee: Aethlon Medical, Inc.
• Inventors: Tullis, Richard H
• Primary Examiner(s): Blumel, Benjamin P
• Application Number:
  US14/490,418
• Publication Number:
  US 20150093289A1
• Time in Patent Office: 1,398 Days
• Field of Search: None
• CPC Class Codes: A61L 2/02 using physical phenomena
• CPC Class Codes: A61L 2/022 Filtration
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents

Abstract

The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual.

Claims

1. A lectin affinity hemodialysis cartridge, comprising:

a filtration chamber configured to receive blood or plasma contaminated with viral particles;

a lectin covalently coupled to agarose or to aminocelite disposed within said filtration chamber; and

a porous hollow fiber membrane, wherein said membrane has pores of 200-500 nm in diameter;

wherein the lectin is selected from the group consisting of;

Galanthus nivalis agglutinin (GNA), Narcissus pseudonarcissus agglutinin (NPA), cyanovirin, and Conconavalin A, and mixtures thereof

wherein the cartridge is configured to remove said viral particles from the blood or plasma.

2. The lectin affinity hemodialysis cartridge of claim 1, wherein said filtration chamber further comprises an inlet port and an outlet port;

wherein a channel of said hollow fiber membrane is in fluidic communication with said inlet and said outlet ports;

said cartridge having an extrachannel space within said chamber which surrounds said hollow fiber membrane; and

wherein said lectin is covalently coupled to agarose or to aminocelite that is disposed within said extrachannel space proximate to an exterior surface of said membrane.

3. The lectin affinity hemodialysis cartridge of claim 1, wherein said membrane has an inside diameter of about 0.3 mm and an outside diameter of about 0.5 mm.

4. The lectin affinity hemodialysis cartridge of claim 1, wherein the cartridge is configured to remove greater than about 50% of viral particles present in the blood or plasma.

5. The lectin affinity hemodialysis cartridge of claim 1, wherein the cartridge is configured to remove greater than about 90% of viral particles in the blood or plasma.